Clinical Trials Browser

Phase 2 × Completed × ALK Gene Rearrangement Positive × Clear all

NCT03779191 2023-07-06

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Phase 2 Completed

ALK Gene Rearrangement Positive